# BDB001-101: Clinical Study of BDB001 as a Mono-therapy or in Combination With Pembrolizumab

> **NCT03486301** · PHASE1 · COMPLETED · sponsor: **Eikon Therapeutics** · enrollment: 87 (actual)

## Conditions studied

- Tumor, Solid

## Interventions

- **DRUG:** BDB001 (EIK1001)
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03486301
- **Lead sponsor:** Eikon Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-15
- **Primary completion:** 2024-03-31
- **Final completion:** 2024-04-30
- **Target enrollment:** 87 (ACTUAL)
- **Last updated:** 2025-11-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03486301

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03486301, "BDB001-101: Clinical Study of BDB001 as a Mono-therapy or in Combination With Pembrolizumab". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03486301. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*